(IFF) International Flavors - NYSE

Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 19.360m USD | Total Return: 3.6% in 12m

Flavors, Fragrances, Enzymes, Probiotics
Total Rating 51
Safety 75
Buy Signal -0.66
Specialty Chemicals
Industry Rotation: +1.8
Market Cap: 19.4B
Avg Turnover: 155M
Risk 3d forecast
Volatility28.8%
VaR 5th Pctl4.56%
VaR vs Median-3.30%
Reward TTM
Sharpe Ratio0.15
Rel. Str. IBD48.8
Rel. Str. Peer Group44.9
Character TTM
Beta0.560
Beta Downside0.496
Hurst Exponent0.533
Drawdowns 3y
Max DD42.62%
CAGR/Max DD0.03
CAGR/Mean DD0.07
EPS (Earnings per Share) EPS (Earnings per Share) of IFF over the last years for every Quarter: "2021-06": 1.5, "2021-09": 1.47, "2021-12": 1.1, "2022-03": 1.69, "2022-06": 1.54, "2022-09": 1.36, "2022-12": 0.97, "2023-03": 0.87, "2023-06": 0.86, "2023-09": 0.89, "2023-12": 0.72, "2024-03": 1.13, "2024-06": 1.16, "2024-09": 0.62, "2024-12": 0.97, "2025-03": -3.98, "2025-06": 1.15, "2025-09": 1.05, "2025-12": 0.8, "2026-03": 1.25,
Last SUE: 0.11
Qual. Beats: 0
Revenue Revenue of IFF over the last years for every Quarter: 2021-06: 3089, 2021-09: 3071, 2021-12: 3031, 2022-03: 3226, 2022-06: 3307, 2022-09: 3063, 2022-12: 2844, 2023-03: 3027, 2023-06: 2929, 2023-09: 2820, 2023-12: 2703, 2024-03: 2899, 2024-06: 2889, 2024-09: 2925, 2024-12: 2771, 2025-03: 2843, 2025-06: 2764, 2025-09: 2694, 2025-12: 2589, 2026-03: 2741,
Rev. CAGR: -2.58%
Rev. Trend: -88.6%
Last SUE: 2.64
Qual. Beats: 4

Warnings

Choppy Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: IFF International Flavors

International Flavors & Fragrances (IFF) is a global manufacturer of flavors, fragrances, and specialty ingredients, operating through four segments: Taste, Food Ingredients, Health & Biosciences, and Scent. The Taste segment produces savory, beverage, sweet, and dairy flavor systems, as well as spices and seasonings. The Food Ingredients segment supplies natural, artificial, and plant-based specialty ingredients, including antioxidants, antimicrobials, proteins, emulsifiers, and sweeteners. The Health & Biosciences segment provides enzymes, food cultures, probiotics, and ingredients for animal nutrition and grain processing. The Scent segment creates fragrance compounds and ingredients. The company was founded in 1909 and is headquartered in New York.

IFF operates as a business-to-business supplier within the specialty chemicals sector, selling ingredients and formulations to consumer goods manufacturers (such as food, beverage, personal care, and household product companies) rather than directly to end consumers. Its products are typically incorporated in small quantities into finished goods, making the flavors and fragrances industry highly dependent on R&D capabilities and long-standing customer relationships.

Headlines to Watch Out For
  • IFF accelerates divestitures to reduce leverage from N&B deal
  • Health & Biosciences margin recovery drives segment profitability
  • Scent and Taste volumes weaken on softer global consumer demand
Piotroski VR-10 (Strict) 5.5
Net Income: 852.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.43 > 1.0
NWC/Revenue: 16.61% < 20% (prev 35.23%; Δ -18.62% < -1%)
CFO/TA 0.04 > 3% & CFO 980.0m > Net Income 852.0m
Net Debt (5.87b) to EBITDA (2.00b): 2.94 < 3
Current Ratio: 1.49 > 1.5 & < 3
Outstanding Shares: last quarter (257.0m) vs 12m ago 0.39% < -2%
Gross Margin: 36.35% > 18% (prev 36.18%; Δ 0.16% > 0.5%)
Asset Turnover: 40.40% > 50% (prev 40.43%; Δ -0.03% > 0%)
Interest Coverage Ratio: 5.06 > 6 (EBIT TTM 1.02b / Interest Expense TTM 202.0m)
Altman Z'' 1.64
A: 0.07 (Total Current Assets 5.44b - Total Current Liabilities 3.65b) / Total Assets 25.1b
B: -0.13 (Retained Earnings -3.35b / Total Assets 25.1b)
C: 0.04 (EBIT TTM 1.02b / Avg Total Assets 26.7b)
D: 1.28 (Book Value of Equity 14.1b / Total Liabilities 11.0b)
Altman-Z'' = 1.64 = BB
Beneish M -2.90
DSRI: 1.12 (Receivables 2.01b/1.89b, Revenue 10.8b/11.4b)
GMI: 1.00 (GM 36.18% / 36.35%)
AQI: 1.11 (AQ_t 0.60 / AQ_t-1 0.54)
SGI: 0.94 (Revenue 10.8b / 11.4b)
TATA: -0.01 (NI 852.0m - CFO 980.0m) / TA 25.1b)
Beneish M = -2.90 (Cap -4..+1) = A
What is the price of IFF shares?

As of June 26, 2026, the stock is trading at USD 75.08 with a total of 1,125,313 shares traded. Over the past week, the price has changed by -0.75%, over one month by -0.52%, over three months by +6.74% and over the past year by +3.59%.

Current recommended Stop Loss: 71.60 (which is 4.6% or 1.5 ATR below the current price).

Is IFF a buy, sell or hold?

International Flavors has received a consensus analysts rating of 4.32. Therefore, it is recommended to buy IFF.

  • StrongBuy: 10
  • Buy: 5
  • Hold: 4
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the IFF price?
Analysts Target Price 91.7 22.1%
International Flavors (IFF) - Fundamental Data Overview as of 26 June 2026
Market Cap USD = 19.4b (19.4b USD * 1.0 USD.USD)
P/E Trailing = 23.4768
P/E Forward = 16.8634
P/S = 1.7946
P/B = 1.3711
P/EG = 0.9022
Revenue TTM = 10.8b USD
EBIT TTM = 1.02b USD
EBITDA TTM = 2.00b USD
Long Term Debt = 4.74b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08b USD (from shortTermDebt, last quarter)
Debt = 6.43b USD (from shortLongTermDebtTotal, last quarter) + Leases 618.0m
Net Debt = 5.87b USD (calculated: Debt 6.43b - CCE 562.0m)
Enterprise Value = 25.2b USD (19.4b + Debt 6.43b - CCE 562.0m)
Interest Coverage Ratio = 5.06 (Ebit TTM 1.02b / Interest Expense TTM 202.0m)
EV/FCF = 63.40x (Enterprise Value 25.2b / FCF TTM 398.0m)
FCF Yield = 1.58% (FCF TTM 398.0m / Enterprise Value 25.2b)
FCF Margin = 3.69% (FCF TTM 398.0m / Revenue TTM 10.8b)
Net Margin = 7.90% (Net Income TTM 852.0m / Revenue TTM 10.8b)
Gross Margin = 36.35% ((Revenue TTM 10.8b - Cost of Revenue TTM 6.87b) / Revenue TTM)
Gross Margin QoQ = 37.14% (prev 34.38%)
Tobins Q-Ratio = 1.00 (Enterprise Value 25.2b / Total Assets 25.1b)
Interest Expense / Debt = 3.14% (Interest Expense 202.0m / Debt 6.43b)
Taxrate = 18.66% (39.0m / 209.0m)
NOPAT = 832.1m (EBIT 1.02b * (1 - 18.66%))
Current Ratio = 1.49 (Total Current Assets 5.44b / Total Current Liabilities 3.65b)
Debt / Equity = 0.46 (Debt 6.43b / totalStockholderEquity, last quarter 14.1b)
Debt / EBITDA = 2.94 (Net Debt 5.87b / EBITDA 2.00b)
Debt / FCF = 14.76 (Net Debt 5.87b / FCF TTM 398.0m)
Total Stockholder Equity = 14.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.19% (Net Income 852.0m / Total Assets 25.1b)
RoE = 5.99% (Net Income TTM 852.0m / Total Stockholder Equity 14.2b)
RoCE = 5.39% (EBIT 1.02b / Capital Employed (Equity 14.2b + L.T.Debt 4.74b))
RoIC = 3.78% (NOPAT 832.1m / Invested Capital 22.0b)
WACC = 6.60% (E(19.4b)/V(25.8b) * Re(7.95%) + D(6.43b)/V(25.8b) * Rd(3.14%) * (1-Tc(0.19)))
Discount Rate = 7.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.20 | Cagr: 0.35%
[DCF] Terminal Value 73.10% ; FCFF base≈466.4m ; Y1≈409.0m ; Y5≈330.5m
 [DCF] Fair Price = N/A (negative equity: EV 5.30b - Net Debt 5.87b = -568.8m; debt exceeds intrinsic value)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.11 | # QB: 0
Revenue Correlation: -88.62 | Revenue CAGR: -2.58% | SUE: 2.64 | # QB: 4
EPS current Quarter (2026-06-30): EPS=1.12 | Chg30d=+0.16% | Revisions=-57% | Analysts=12
EPS next Quarter (2026-09-30): EPS=1.15 | Chg30d=+0.71% | Revisions=-14% | Analysts=12
EPS current Year (2026-12-31): EPS=4.50 | Chg30d=+0.63% | Revisions=+41% | GrowthEPS=+7.1% | GrowthRev=-1.4%
EPS next Year (2027-12-31): EPS=4.81 | Chg30d=-0.93% | Revisions=+37% | GrowthEPS=+7.0% | GrowthRev=+3.0%
[Analyst] Revisions Ratio: -57%